LENSAR, Inc. Share Price

Equities

LNSR

US52634L1089

Advanced Medical Equipment & Technology

Market Closed - Nasdaq 02:00:00 27/04/2024 am IST 5-day change 1st Jan Change
3.24 USD -5.54% Intraday chart for LENSAR, Inc. +0.31% -7.69%
Sales 2024 * 51.3M 4.28B Sales 2025 * 62.7M 5.23B Capitalization 36.92M 3.08B
Net income 2024 * -11M -917M Net income 2025 * -9M -750M EV / Sales 2024 * 0.72 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 0.59 x
P/E ratio 2024 *
-3.13 x
P/E ratio 2025 *
-3.81 x
Employees 130
Yield 2024 *
-
Yield 2025 *
-
Free-Float 82.53%
More Fundamentals * Assessed data
Dynamic Chart
1 day-5.54%
1 week+0.31%
Current month-4.62%
1 month-13.83%
3 months-15.62%
6 months+49.31%
Current year-7.69%
More quotes
1 week
3.10
Extreme 3.1
3.60
1 month
2.67
Extreme 2.67
3.64
Current year
2.67
Extreme 2.67
5.30
1 year
1.80
Extreme 1.8
5.30
3 years
1.80
Extreme 1.8
8.98
5 years
1.80
Extreme 1.8
12.71
10 years
1.80
Extreme 1.8
12.71
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 01/10/01
Director of Finance/CFO 56 01/20/01
Chief Operating Officer 52 01/08/01
Members of the board TitleAgeSince
Chief Executive Officer 68 01/10/01
Director/Board Member 54 25/23/25
Director/Board Member 76 02/18/02
More insiders
Date Price Change Volume
26/24/26 3.24 -5.54% 76,316
25/24/25 3.43 +5.21% 44,877
24/24/24 3.26 +2.52% 8,334
23/24/23 3.18 -2.15% 13,632
22/24/22 3.25 +0.62% 19,344

Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST

More quotes
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. Its product portfolio consists of the LENSAR Laser System and ALLY Adaptive Cataract Treatment System (ALLY System) and its associated consumable components. The system incorporates a range of technologies designed to assist the surgeon in obtaining visual outcomes. The consumable portion of the system consists of a disposable patient interface device kit. The ALLY System is designed to combine its femtosecond laser technology features with enhanced laser capabilities into a single small unit that allows surgeons to perform a femtosecond laser assisted cataract procedure in a single operating room or in-office surgical suite. Its system is used across surgeons, hospital outpatient surgical facilities and ambulatory surgery centers.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.24 USD
Average target price
8 USD
Spread / Average Target
+146.91%
Consensus